These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 34531304)

  • 1. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
    RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus.
    Rendas-Baum R; Chen WH; Gairy K; Anderson S; Henning C; Hammer A; Kosinski M
    Lupus Sci Med; 2024 May; 11(1):. PubMed ID: 38724182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A; Stohl W; Schwarting A; Okada M; Scheinberg M; van Vollenhoven R; Hammer AE; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.
    Maslen T; Bruce IN; D'Cruz D; Ianosev M; Bass DL; Wilkinson C; Roth DA
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33568389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses.
    Zheng J; Gu J; Su Y; Li Y; Li X; Xiong C; Cao H; Quasny H; Chu M; Curtis P; DeRose K; Kurrasch R; Meizlik P; Roth DA; Zhang F
    Mod Rheumatol; 2023 Jul; 33(4):751-757. PubMed ID: 36208293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
    Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
    Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
    Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B
    Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
    van Vollenhoven RF; Petri MA; Cervera R; Roth DA; Ji BN; Kleoudis CS; Zhong ZJ; Freimuth W
    Ann Rheum Dis; 2012 Aug; 71(8):1343-9. PubMed ID: 22337213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
    Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
    Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia.
    Suh CH; Lee Y; Yoo SB; Quasny H; Navarro Rojas AA; Hammer A; Song YW; Kang YM; Cho CS; Park W; Kwok SK; Lee SG; Chung WT; Bae SC
    Int J Rheum Dis; 2024 Jan; 27(1):e14997. PubMed ID: 38140854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
    Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW
    Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.
    Parodis I; Lindblom J; Levy RA; Zen M; Cetrez N; Gomez A; Oon S; Henning C; Khamashta M; Quasny HA; Chauhan D; Askanase A; van Vollenhoven R; Nikpour M
    Lancet Rheumatol; 2024 Nov; 6(11):e751-e761. PubMed ID: 39208825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
    Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D
    Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D
    Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
    Abrahamowicz M; Esdaile JM; Ramsey-Goldman R; Simon LS; Strand V; Lipsky PE
    Arthritis Rheumatol; 2018 Sep; 70(9):1450-1458. PubMed ID: 29648686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
    Manzi S; Sánchez-Guerrero J; Merrill JT; Furie R; Gladman D; Navarra SV; Ginzler EM; D'Cruz DP; Doria A; Cooper S; Zhong ZJ; Hough D; Freimuth W; Petri MA;
    Ann Rheum Dis; 2012 Nov; 71(11):1833-8. PubMed ID: 22550315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.